Severe Hypocalcemia After Denosumab Treatment Leading to Refractory Ventricular Tachycardia
Document Type
Abstract
Publication Date
9-1-2025
Abstract
Description: Case Report: A 70-year-old man with multiple myeloma developed severe hypocalcemia 1 week after receiving denosumab. Despite calcium supplementation, he developed refractory ventricular tachycardia. Echocardiography showed a preserved ejection fraction, and his calcium levels eventually stabilized after intensive treatment with calcium and vitamin D. Discussion: Denosumab-induced hypocalcemia, though rare, can lead to serious cardiovascular events, including ventricular tachycardia. Prolonged serum denosumab concentrations contribute to persistent hypocalcemia. Early recognition and correction of hypocalcemia are crucial to prevent life-threatening complications. Conclusion: Denosumab-induced hypocalcemia can lead to severe complications like ventricular tachycardia. Early screening, correction of calcium and vitamin D levels, and close monitoring are critical to managing this risk.
Publication Title
Endocrine Practice
Volume
31
Issue
9 Supplement
First Page
S166
Last Page
S166
Recommended Citation
Baral, B., Bruges, P., & Parajuli, S. (2025). Severe Hypocalcemia After Denosumab Treatment Leading to Refractory Ventricular Tachycardia. Endocrine Practice, 31 (9 Supplement), S166-S166. https://doi.org/https://doi.org/10.1016/j.eprac.2025.05.461
Comments
AACE Annual Meeting 2025 held 2025-05-15 to 2025-05-17 in Orlando, FL, USA.